Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Health GroupHKSE:00673 24 PB Ratio is 10.81 as of Aug. 12, 2026, which is 220% above its 10-year median of 3.38. GuruFocus rates HKSE:00673 with a GF Score™ of 24/100 and a GF Value™ of HK$0.24 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 113 Medical Distribution companies, China Health Group ranks worse than 95.58% on this metric.
China Health Group Ltd stock PB Ratio (=9.73) is close to 10-year high of 10.36.
The historical rank and industry rank for China Health Group's PB Ratio or its related term are showing as below:
HKSE:00673'
s PB Ratio Range Over the Past 10 Years
Min: 1.45 Med: 3.38 Max: 10.36
Current: 10
During the past 13 years, China Health Group's highest PB Ratio was 10.36. The lowest was 1.45. And the median was 3.38.
HKSE:00673's PB Ratio is ranked worse than 95.58% of 113
companies
in the Medical Distribution industry
Industry Median: 1.03
vs HKSE:00673: 10.00
During the past 3 years, the average Book Value Per Share Growth Rate was -27.90% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of China Health Group was 54.50% per year. The lowest was -48.10% per year. And the median was -21.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
China Health Group PB Ratio Related Terms
China Health Group PB Ratio Historical Data
* Premium members only.
The historical data trend for China Health Group's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Distribution subindustry, China Health Group's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
China Health Group PB Ratio vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, China Health Group's PB Ratio distribution charts can be found below:
* The bar in red indicates where China Health Group's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
China Health Group (HKSE:00673) has a PB Ratio of 10.81 as of Aug. 12, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Health Group and its competitors. This is 220% above median its historical median of 3.38. Over the past decade, China Health Group's PB Ratio has ranged from 1.45 to 10.36. According to the industry distribution chart, China Health Group ranks #108 out of 113 companies in the Medical Distribution industry, placing it in the top 95.6%.
Is China Health Group's PB Ratio too high?
China Health Group's current PB Ratio of 10.81 is 220% above median its 10-year median of 3.38. Over the past 10 years, this metric has ranged from a low of 1.45 to a high of 10.36. The Medical Distribution industry median PB Ratio is 1.03. China Health Group's value of 10.81 is 949.5% above this industry median. Based on the distribution chart, China Health Group ranks #108 out of 113 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, China Health Group has a GF Score™ of 24/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does China Health Group's PB Ratio compare to MCK and COR?
According to the Medical Distribution industry distribution chart, China Health Group ranks #108 out of 113 companies for PB Ratio. This places China Health Group in the lower half of its industry. The industry median PB Ratio is 1.03. China Health Group's value of 10.81 is 949.5% above this benchmark. Historically, China Health Group's own PB Ratio has ranged from 1.45 to 10.36 over the past decade. While the company's 10-year median is 3.38 vs. the industry median of 1.03, China Health Group has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Distribution company?
The median PB Ratio among Medical Distribution companies is 1.03, based on 113 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. China Health Group's current PB Ratio of 10.81 is 949.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on China Health Group and its competitors. For the Medical Distribution industry, the median PB Ratio is 1.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. China Health Group's current PB Ratio is 10.81, which is 220% above median its own 10-year median of 3.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Health Group stock overvalued right now?
Based on GuruFocus' analysis, China Health Group (HKSE:00673) is currently considered Significantly Overvalued. The stock's GF Value™ is HK$0.24, compared to a current price of HK$0.40 — trading 66.7% above its estimated fair value. The current PB Ratio is 10.81, which is 220% above median its 10-year median of 3.38 and 949.5% above the Medical Distribution industry median of 1.03. China Health Group's overall GF Score™ is 24/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For China Health Group (HKSE:00673), the current PB Ratio is 10.81 as of Aug. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Health Group (HKSE:00673) Overvalued in 2026?
Based on GuruFocus' analysis, China Health Group stock appears to be overvalued.
The current stock price of HK$0.40 is trading 66.7% above its estimated GF Value™ of HK$0.24.
GuruFocus considers China Health Group to be Significantly Overvalued.
Key valuation signals for HKSE:00673:
PB Ratio: 10.81 (220% above median its 10-year median of 3.38)
GF Value™: HK$0.24 vs. price of HK$0.40 (66.7% above fair value)
Industry Position: 949.5% above the Medical Distribution median (#108 of 113)
No single metric tells the full story. See the HKSE:00673 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Health Group Ltd is an investment holding company. It is principally engaged in the distribution and service of medical equipment and consumables, provision of hospital operation and management services, and business factoring. It operates in the business in four segments: medical equipment and consumables distribution and service business; hospital operation and management services business; business service; and research and development and sale of functional food. It derives a majority of revenue from the Distribution and service in the medical equipment and consumables segment. Geographically, the group derives its revenue from the PRC.
24GF Score
Get the complete analysis for HKSE:00673
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:00673 has been successfully added to your 
